ROYALTY AGREEMENT
Exhibit 10.1
This Royalty Agreement ("Agreement") is made as of October 1, 2013 (“Effective Date”) by and between Asterias Biotherapeutics, Inc., a Delaware corporation (“Asterias”), and Geron Corp., a Delaware corporation (“Geron”).
RECITALS
WHEREAS, Asterias, BioTime, Inc. and Geron have entered into that certain Asset Contribution Agreement, dated January 4, 2013 (the “Asset Contribution Agreement”), pursuant to which Geron has transferred and assigned certain patents and patent applications to Asterias in exchange for shares of Asterias common stock; and
WHEREAS, Asterias has agreed to enter into this Agreement and pay to Geron royalties on product sales and a share of royalties received from third party licensees on the sale products covered by the Geron patents, on the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the Parties hereto agree as follows:
ARTICLE 1 ‑ DEFINITIONS
Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Asset Contribution Agreement. The following defined terms shall have the meanings ascribed to them in this Article 1:
1.1 “Affiliate” means, with respect to Geron or Asterias, any corporation, limited liability company, limited partnership or other entity in control of, controlled by, or under common control with such party.
1.2 “Combination Product” means any Product which includes one or more active ingredients other than a Product in combination with a Product, including a fixed-dose combination product.
1.3 “Confidential Information” means any and all information that is contained in any report under Section 3.1, or disclosed by Asterias or any of its Affiliates to Geron or its Representatives in connection with any audit under Section 3.2.
1.4 "Contributed Patents" means all of the patents, patent applications and patent rights to inventions identified on Schedule 1 and all active prosecution cases related thereto.
1.5 “Excluded Product” means any Product covered by one or more patents licensed to or from Geron under the cross-license among Geron, ES Cell International Pte Ltd. and Cell Cure Neurosciences, Ltd.
1.6 “First Commercial Sale” means the first sale for end-use or consumption of a Product.
1.7 "Net Sales" means the total gross amount invoiced and paid to Asterias or any Affiliate of Asterias for sales or transfers of Products to an unrelated third party anywhere in the world,
(a) less deductions for:
(i) freight, postage and duties and transportation charges directly related to the Products sold (including handling and insurance with respect thereto);
(ii) sales, value added and excise taxes or customs paid, and any other similar governmental charges imposed upon the sale of the Products that are not recoverable;
(iii) allowances, chargebacks or credits actually granted by Asterias or its Affiliates to end-users not in excess of the selling price of Products, on account of rejection, outdating, recalls or return of Products; and
(iv) rebates, reimbursements, fees or similar payments: (1) to wholesalers and other distributors, pharmacies and other retailers, buying groups (including group purchasing organizations), health care insurance carriers, pharmacy benefit management companies, health maintenance organizations, hospitals, clinics, government agencies or authorities or other institutions or health care organizations; or (2) to patients and other third parties arising in connection with any program applicable to Products under which the Asterias or its Affiliates provide to low income, uninsured or other patients the opportunity to obtain one or more Products at a reduced cost.
For the avoidance of doubt, if a single item falls into more than one of the categories set forth in clauses “(a)(i)” through “(a)(iv)” above, such item may not be deducted more than once. For purposes of determining Net Sales, a Product shall be deemed to be sold when invoiced.
(b) Net Sales for any Combination Product in a country shall be calculated as follows:
(i) Where all active ingredients in such Combination Product are sold separately in the country, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product in such country as determined above by the fraction A/(A+B), where A is the net invoice price of the Product as sold separately in such country, and B is the sum of the net invoice prices of the other active ingredients in the combination.
(ii) If the Product component of the Combination Product is sold separately in the country, but none of such other active ingredient(s) is sold separately in such country, Net Sales for the purpose of determining royalties due hereunder for the Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/C, where A is the net invoice price of such Product component as sold separately, and C is the net invoice price of the Combination Product.
2
(iii) If the Product component of the Combination Product is not sold separately in the country, but the other active ingredient(s) are sold separately in such country, Net Sales for the purpose of determining royalties due hereunder for the Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction (C-D)/C, where: C is the net invoice price, in such country, for the Combination Product, and D is the sum of the net invoice prices charged for the other active ingredients in the Combination Product.
(iv) If none of the Product component and the other active ingredients are sold separately in the country, Net Sales for the purposes of determining royalties due hereunder for the Combination Product will be determined by mutual agreement of the parties, according to the formula D/(D+E), where D is the fair market value of the portion of the Combination Products that contains the Product, and E is the fair market value of the portion of the Combination Product containing the other active ingredients in such Combination Product. In applying the foregoing formulas, Asterias (or its Affiliate if the sale was by an Affiliate) shall act in good faith and accordance with Asterias’ (or its Affiliate if the sale was by an Affiliate) regular accounting methods, consistently applied.
(c) If a Product is sold for consideration other than cash, the Net Sales from such sale shall be deemed the then fair market value of such Product.
1.8 “Partially Excluded Product” means any Product which includes one or more Products that are not Excluded Products in combination with one or more Excluded Products.
1.9 "Product" means any composition or product the manufacture, use, sale, offer for sale, or importation of which would constitute, but for ownership or licensed rights to use one or more of the Contributed Patents, an infringement of any Valid Claim under one or more Contributed Patents. The term “Product”, as used herein, shall include Combination Products.
1.10 “Representatives” means, with respect to Geron or Asterias, such party’s Affiliates and its and their respective officers, directors, employees, agents, attorneys, accountants and advisors.
1.11 “Sales Agent” means any distributor, independent sales representative, consignee or other agent retained in writing by Asterias or any Affiliate of Asterias for the purpose of selling Products on behalf of Asterias and Asterias’ Affiliates. For the avoidance of doubt, the foregoing shall not include collaborators, partners or sublicensees of Asterias or Asterias’ Affiliates who sell Products other than on behalf of Asterias or Asterias’ Affiliates.
1.12 "Term" means the period of time beginning on the Effective Date and ending on the expiration or termination date of the last Valid Claim such that no Valid Claims remain in effect in any country.
3
1.13 “Valid Claim” shall mean a claim of an issued and unexpired patent included within the Contributed Patents, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.
For purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires: (a) the use herein of the plural shall include the single and vice versa and the use of the masculine shall include the feminine; (b) unless otherwise set forth herein, the use of the terms “including,” “includes,” or “include” means “including but not limited to,” “includes but is not limited to,” or “include but not be limited to,” respectively; and (c) the words “herein,” “hereof,” “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular provision. Additional terms may be defined throughout this Agreement.
ARTICLE 2- ROYALTIES
2.1 Royalties.
(a) Commencing on the First Commercial Sale of each Product by Asterias, an Affiliate of Asterias, or a Sales Agent, Asterias shall pay Geron a royalty in the amount of four percent (4%) of Net Sales of such Product.
(b) In the case of sales of Products by any individual or entity other than a Sales Agent, Asterias or any Affiliate of Asterias (any such individual or entity, a “non-Affiliate”) where Asterias or any Affiliate of Asterias receives a royalty or other cash payment in respect of such Product sales, Asterias shall pay Geron fifty percent (50%) of all such royalties and other cash payments received by Asterias or such Affiliate of Asterias in respect to such Product sales; provided, however, that royalties or other such payments derived from the sales of Combination Products shall be calculated on the basis set forth for Net Sales for Combination Products specified in clauses “(b)(i)” to “(b)(iv)” of Section 1.7. The parties acknowledge and agree that in no event will Asterias pay Geron an amount in excess of any royalty or other cash payment received by Asterias or such Affiliate of Asterias, less all cash payments owed by Asterias or such Affiliate of Asterias to third parties, in each case, with respect to such Product sales.
(c) Geron will not be entitled to receive any royalties or other cash payments pursuant to this Agreement with respect to Excluded Products that are not Partially Excluded Products. With respect to Partially Excluded Products, any royalty on Net Sales pursuant to Section 2.1(a) or royalty or other cash payment derived from the sales of any Partially Excluded Products pursuant to Section 2.1(b) shall be calculated on the basis set forth for Net Sales for Combination Products specified in clauses “(b)(i)” to “(b)(iv)” of Section 1.7 as if the Excluded Product(s) (together with any other active ingredient(s) that are not Products in the event that such Partially Excluded Product also constitutes a Combination Product) were the active ingredients that are not Products.
4
(d) Asterias’ obligation to pay royalties or other cash payments on Net Sales, or with respect to royalties or other cash payments received from any non-Affiliate with respect to any Product, shall expire on a country by country basis upon the expiration of the last to expire Valid Claim covering such Product in any country where the Product is sold.
(e) Geron will not be entitled to receive any payments under this Section 2 with respect to any payments or reimbursements received by Asterias, any Affiliate of Asterias or any Sales Agent for advertising or similar marketing and promotional expenses.
ARTICLE 3 – REPORTS, RECORDS AND PAYMENTS
3.1 Reports. After the First Commercial Sale of a Product, Asterias shall submit to Geron quarterly reports within sixty (60) days after the end of each calendar quarter. Each report shall set forth Product sales by Asterias and each of its Affiliates in the most recently completed calendar quarter, and shall show:
(a) the gross sales and Net Sales (including all deductions used to calculate Net Sales, and the amounts of each such deduction) during the most recently completed calendar quarter and the royalties, in US dollars, payable with respect thereto;
(b) the amount of each Product sold; and
(c) any amounts due and payable to Asterias during the most recently completed calendar quarter, in US dollars, on account of Products sold by non-Affiliates, where Asterias received a royalty or other cash payment on Product sales; and
(d) the exchange rates used to convert foreign currencies into US dollars.
If no Products have been sold by Asterias and its Affiliates and no royalties or other cash payments have been received by Asterias or its Affiliates with respect to Products sold by non-Affiliates during any reporting period, Asterias shall so report.
3.2 Records & Audits.
(a) Asterias shall keep, and shall require its Affiliates to keep, accurate and correct records of all Products sold. Asterias shall also keep accurate and correct records of all royalties received on account of Products sold by non-Affiliates where Asterias receives a royalty or other cash payment on Product sales. Such records shall be retained by Asterias for at least three (3) years following a given reporting period.
5
(b) All records described in Section 3.2(a) shall be available during normal business hours for inspection at the expense of Geron by a certified public accountant selected by Geron and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments due. Such inspector shall not disclose to Geron any information other than information relating to the accuracy of reports and payments made under this Agreement, and shall sign a reasonably acceptable confidentiality agreement with Asterias obligating such inspector to retain such information in confidence pursuant to such confidentiality agreement. In the event that any such inspection shows an under reporting and underpayment in excess of five percent (5%) for any twelve-month (12-month) period, then Asterias shall pay the cost of the audit as well as any additional sum that would have been payable to Geron had the Asterias reported correctly, plus an interest charge at a rate of rate per annum 300 basis points over the “prime rate” (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid. Such interest shall be calculated from the date the correct payment was due to Geron up to the date when such payment is actually made by Asterias or an Affiliate. For underpayment not in excess of five percent (5%) for any twelve-month (12-month) period, Asterias shall pay the difference within thirty (30) days without interest charge or inspection cost.
(c) Asterias acknowledges and agrees that, due to the unique nature of the records subject to audit under Section 3.2(b), Geron would be incapable of verifying reports and payments made by Asterias pursuant to this Agreement without access to such records, that there may be no adequate remedy at law for any breach of Asterias’ obligations under Section 3.2(b), and therefore, that upon any breach thereof by Asterias, Geron shall be entitled to seek appropriate equitable relief in addition to whatever remedies it might have at law.
3.3 Payments.
(a) All royalties due Geron shall be paid in United States dollars. When Net Sales or royalties are denominated in currencies other than United States dollars, Asterias shall first determine the royalty in the currency of the country in which Products were sold or royalties were paid and then convert the amount into equivalent United States dollars, using the exchange rate published on Bloomberg at 5:00pm California time on the last business day of the applicable period in question or in the Wall Street Journal on such date if not so published on Bloomberg.
(b) Asterias shall pay all payments due hereunder quarterly within sixty (60) calendar days after the end of each calendar quarter. Each such payment shall be for earned payments accrued within Asterias 's most recently completed calendar quarter.
ARTICLE 4– TERM AND TERMINATION
This Agreement shall be effective on the Effective Date and shall terminate on the expiration of the Term. Asterias’ obligation under this Article 4 shall survive termination of this Agreement as follows: (a) with respect to paying royalties and providing reports, until the last required quarterly report has been provided and all royalties due with respect to Net Sales or royalties received by Asterias from non-Affiliates with respect to sales of Products during the Term have been paid; (b) with respect to Geron’s right to audit the books and records of Asterias and its Affiliates, for a period of one year, and (c) with respect to retaining books and records of Product sales and royalties received, for three years.
6
ARTICLE 5 - CONFIDENTIALITY
5.1 During the Term and for a period of three (3) years thereafter, Geron shall not disclose any Confidential Information to any third party (other than Geron’s Representatives who have a need to know such Confidential Information) or use such Confidential Information to compete with Asterias; provided, however, that this Section 5.1 shall not restrict Geron from performing any obligation or exercising any right under this Agreement and shall not restrict Geron’s individual Representatives from using Residual Knowledge. For purposes of this Agreement, “Residual Knowledge” means ideas, concepts, know-how, or techniques related to the Confidential Information that are retained in the unaided memories of the Geron’s individual Representatives who have had access to the Confidential Information. An individual Representative’s memory is considered unaided if the employee has not intentionally memorized the relevant Confidential Information for the purpose of retaining and subsequently using or disclosing it. Geron shall not direct any of its individual Representatives to use or practice any Residual Knowledge. In protecting the Confidential Information from unauthorized disclosure to any third party, Geron shall use at least the same degree of care as it uses in preventing the unauthorized disclosure of its own confidential information.
5.2 Notwithstanding anything contained herein to the contrary, Confidential Information shall not include information that: (a) is or becomes publicly available (other than through a breach of this Agreement); (b) was known to or in the possession of Geron or any of its Representatives at the time of disclosure to Geron by any Representative of Asterias or by any Representative of any Affiliate of Asterias; (c) is independently developed or acquired by Geron or any of its Representatives without the use of Confidential Information; (d) is disclosed with the prior written approval of Asterias or any of its Representatives; or (e) becomes known to Geron or its Representatives from a third party (other than a former officer, director or employee of Geron or its Affiliates who knew such information during the term of their office, directorship or employment with Geron or its Affiliates) on a nonconfidential basis without breach of this Agreement by Geron.
5.3 Notwithstanding anything contained herein to the contrary, Geron shall be permitted to disclose Confidential Information to the extent required by law or pursuant to the order or legal process of a court, administrative agency, or other governmental body (including by deposition, interrogatory, request for documents, subpoena, civil investigation, demand or similar process), or any rule, regulation, policy statement or other formal demand of any national securities exchange, market or automated quotation system; provided, that, to the extent permitted by applicable law or any order or requirement of a court, administrative agency or other governmental body, Geron will, as promptly as practicable, provide Asterias with prior written notice of such requirement so that Asterias may seek a protective or other order at its sole expense, or waive compliance with the terms of this Agreement with respect to such disclosure. If such protective order is not timely obtained, or if Asterias waives compliance with the provisions hereof or fails to promptly respond to Geron’s written notice, Asterias will, without liability under this Agreement, furnish only that portion of the Confidential Information that it is advised by its outside legal counsel is legally required and will exercise commercially reasonable efforts to obtain assurance that confidential treatment, if available, will be accorded such Confidential Information. Notwithstanding anything to the contrary contained herein, Geron may disclose Confidential Information to the extent required by federal or state securities laws or reporting obligations to the United States Securities and Exchange Commission.
7
5.4 Except as required by law, including but not limited to federal and state securities laws or reporting obligations to the United States Securities and Exchange Commission, or pursuant to the order or requirement of a court, administrative agency or other governmental body (including by deposition, interrogatory, request for documents, subpoena, civil investigation, demand or similar process), or any rule, regulation, policy statement or other formal demand of any national securities exchange, market or automated quotation system, neither Geron nor Asterias shall publicly disclose any terms and conditions of this Agreement unless expressly authorized to do so in writing by the other party, which authorization shall not be unreasonably withheld. This restriction shall not apply with respect to any terms and conditions of this Agreement that are or become publicly available (other than through a breach of this Agreement).
5.5 Each of Geron and Asterias acknowledge and agree that due to the unique nature of the Confidential Information and the terms and conditions of this Agreement, there may be no adequate remedy at law for any breach of its obligations under this Article 5, and therefore, that upon any breach thereof by the other party, Geron or Asterias shall be entitled to seek appropriate equitable relief in addition to whatever remedies it might have at law.
ARTICLE 6- NOTICES AND OTHER COMMUNICATIONS
Any notice or other communication required to be given to any party will be deemed to have been properly given and to be effective (a) on the date of delivery if delivered by hand, air courier delivery service, confirmed facsimile transmission, or confirmed electronic mail, or (b) four days after being deposited in the United States Mail, certified first class postage prepaid, in each case if sent to the respective addresses, FAX number or email address given below, or to another address as it shall designate by written notice given to the other party in the manner provided in this Article.
|
|
In the case of Asterias:
|
|
|
|
|
000 Xxxxxx Xxx Xxxxxxx, Xxxxx 000
|
|
|
|
Xxxxxxx, Xxxxxxxxxx 00000
|
|
|
|
FAX: (000) 000-0000
|
|
|
|
Attention: Xxxxxx Xxxxxx, Chief Executive Officer
|
|
|
In the case of Geron:
|
Geron Corporation
|
|
|
|
000 Xxxxxxxxxxxx Xxxxx
|
|
|
|
Xxxxx Xxxx, XX 00000
|
|
|
|
FAX: (000) 000-0000
|
|
|
|
Attention: Vice President, Legal
|
8
ARTICLE 7 – GOVERNING LAW AND JURISDICTION
7.1 This Agreement and all claims or causes of action (whether in contract or tort or otherwise) based upon, arising out of or related to this Agreement or the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of California without regard to conflict of laws principles that would result in the application of any law other than the laws of the State of California. Except as provided for in Section 7.2, each of Geron and Asterias: (a) consents to and submits to the exclusive jurisdiction and venue of the Superior Court of the State of California for the County of Santa Xxxxx of the State of California or the United States District Court for the Northern District of California, in any Proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement; (b) agrees that all claims in respect of any such Proceeding shall be heard and determined in any such court; (c) shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court; and (d) shall not bring any Proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court. Each of Geron and Asterias waives any defense of inconvenient forum to the maintenance of any Proceeding so brought and waives any bond, surety or other security that might be required of any other Person with respect thereto. Each of Geron and Asterias hereby agrees that service of any process, summons, notice or document in accordance with the provisions of Article 6 shall be effective service of process for any Proceeding arising out of or relating to this Agreement or any of the transactions contemplated hereby. TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT.
7.2 Notwithstanding anything to the contrary contained in this Agreement, any claim (other than a claim for injunctive or other equitable relief from a court of competent jurisdiction in accordance with Section 7.1) for any breach of Geron’s or Asterias’ obligations or covenants under this Agreement (“Claim”) shall be brought and resolved exclusively in accordance with the provisions of Schedule 10.10(b) of the Asset Contribution Agreement and shall otherwise be governed by the applicable provisions of this Article 7 as if Geron or Asterias were bringing such Claim as a Geron Indemnitee or Asterias Indemnitee, respectively, thereunder; provided, however, that nothing in this Section 7.2 shall prevent any party from seeking injunctive and other equitable relief from a court of competent jurisdiction in compliance with Section 7.1 hereof.
7.3 In the event that any party to this Agreement becomes aware of any event or circumstance that would reasonably be expected to constitute or give rise to any Claim for Damages, the party having the right to bring such Claim (“Claimant”) shall take all commercially reasonable efforts to mitigate and minimize all Damages that may result from the breach giving rise to the Claim (it being understood that nothing in this Agreement shall limit such Claimant’s right to seek recovery from the other party with respect to any costs of such mitigation). Each Claimant shall use reasonable efforts to collect any amounts available under insurance coverage for any Damages for which a Claim may be brought under this Agreement. The amount of any Damages for which a Claim may be brought shall be net of any amounts recovered by the Claimant under insurance policies with respect to such Damages in excess of the sum of: (i) reasonable out-of-pocket costs and expenses relating to collection under such policies; and (ii) any deductible associated therewith to the extent paid or by which insurance proceeds were reduced. “Damages” shall mean any damage, loss, liability, cost, judgment, award, fee (including any legal fee, expert fee, accounting fee or advisory fee) or expense; provided, however, that in no event shall Damages include any special, indirect, incidental or consequential damages except in the case of a violation of Section 5.1.
9
7.4 Subject to any injunction or other equitable remedies that may be available to any party, a party shall not be liable or responsible in any manner whatsoever to the other party with respect to the matters contemplated by this Agreement other than for Claims brought as provided in this Article 7 and subject to the limitations contained therein; provided, however, that no Claim against a party for fraud by such party shall be subject to the limitations of this Article 7.
ARTICLE 8 ‑ MISCELLANEOUS PROVISIONS
8.1 Nothing herein shall be deemed to constitute either party as the agent or representative of the other party.
8.2 The parties hereto acknowledge that this Agreement sets forth the entire Agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument subscribed to by the parties hereto.
8.3 The provisions of this Agreement are severable, and in the event that any provisions of this Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.
8.4 The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.
8.5 This Agreement, and the rights and obligations of Asterias under this Agreement, may not be assigned by Asterias except: (a) with the prior written consent of Geron; (b) in connection with a merger or consolidation of Asterias; or (c) an assignment by Asterias in connection with a sale of all or substantially all of the Contributed Patents. Geron may freely assign this Agreement or any of its rights and obligations under this Agreement; provided, that Geron provides to Asterias a written agreement executed by the assignee agreeing to be bound by all of the terms and conditions of this Agreement in place of the assignor. Subject to the provisions of this Section 8.5, this Agreement shall inure to the benefit of Geron, Asterias and their respective successors and permitted assigns.
[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]
10
IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the Effective Date set forth above.
|
|
||
|
|
|
|
|
By:
|
s/Xxxxxx Xxxxxx
|
|
|
|
Xxxxxx Xxxxxx, Chief Executive Officer
|
|
|
GERON CORPORATION
|
|
|
|
|
|
|
|
By:
|
s/Xxxx Xxxxxxxx
|
|
|
|
Xxxx Xxxxxxxx, Chief Executive Officer
|
|
[SIGNATURE PAGE TO ROYALTY AGREEMENT]
SCHEDULE 1
CONTRIBUTED PATENTS
Notwithstanding anything contained in the Royalty Agreement to the contrary, patents and patent applications marked “(CONSENT REQUIRED)” in this Schedule shall be deemed included on this Schedule and shall be subject to the Royalty Agreement as Contributed Patents only if Geron shall have obtained the prior express written consent of the University of Edinburgh under that certain Research and License Agreement, dated as of May 3, 1999, by and among the Roslin Institute (as predecessor-in-interest to the University of Edinburgh), Geron and Roslin Bio-Med, Ltd. (as predecessor-in-interest to Geron), as amended on October 1, 2002, September 3, 2003 and July 1, 2005, to assign or otherwise transfer such patents and patent applications to Asterias.
|
|
TITLE
|
COUNTRY
|
APPLICATION NUMBER
|
FILING DATE
|
PATENT
NUMBER
|
ISSUE DATE
|
STATUS
|
ADDL.
ASSIGNEE
/ JOINT
OWNER
|
|
061/005
|
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
|
US
|
09/530,346
|
24-Apr-00
|
6,800,480
|
5-Oct-04
|
Issued
|
|
|
061/006D
|
Feeder-Free Culture Method for Embryonic Stem Cells
|
US
|
10/330,873
|
24-Dec-02
|
7,413,902
|
19-Aug-08
|
Issued
|
|
|
061/235AU
|
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
|
AU
|
12771/99
|
23-Oct-98
|
729377
|
17-May-01
|
Issued
|
|
|
061/236CA
|
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
|
CA
|
2307807
|
23-Oct-98
|
2,307,807
|
2-Sep-08
|
Issued
|
|
|
061/237EP
|
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
|
EP
|
98956192.3
|
23-Oct-98
|
|
|
Pending
|
|
|
061/238JP
|
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
|
JP
|
2000-517062
|
23-Oct-98
|
3880795
|
17-Nov-06
|
Issued
|
|
|
061/239JP D
|
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
|
JP
|
2000-185486
|
23-Oct-98
|
3880778
|
17-Nov-06
|
Issued
|
|
|
061/241HK
|
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells
|
HK
|
01100775
|
23-Oct-98
|
|
|
Pending
|
|
|
081/002C
|
Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
|
US
|
09/675,321
|
29-Sep-00
|
6,440,735
|
27-Aug-02
|
Issued
|
|
|
081/003P
|
Method for Identifying and Killing Cancer Cells
|
US
|
10/208,243
|
30-Jul-02
|
7,402,307
|
22-Jul-08
|
Issued
|
|
|
081/004D
|
Cellular Telomerase Vaccine and Its Use for Treating Cancer
|
US
|
11/413,838
|
27-Apr-06
|
7,824,849
|
2-Nov-10
|
Issued
|
|
|
081/202CA
|
Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
|
CA
|
2347067
|
30-Mar-99
|
|
|
Pending
|
|
2
|
081/206CH
|
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen
|
CH
|
999161938
|
30-Mar-99
|
1068296
|
10-Aug-11
|
Issued
|
|
|
081/207DE
|
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen
|
DE
|
999161938
|
30-Mar-99
|
1068296
|
10-Aug-11
|
Issued
|
|
|
081/208FR
|
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen
|
FR
|
999161938
|
30-Mar-99
|
1068296
|
10-Aug-11
|
Issued
|
|
|
081/209GB
|
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen
|
GB
|
999161938
|
30-Mar-99
|
1068296
|
10-Aug-11
|
Issued
|
|
|
081/210IT
|
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen
|
IT
|
999161938
|
30-Mar-99
|
1068296
|
10-Aug-11
|
Issued
|
|
|
090/004D
|
Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
|
US
|
11/010,230
|
10-Dec-04
|
7,560,281
|
14-Jul-09
|
Issued
|
|
|
090/005C
|
Neural Cell Populations from Primate Pluripotent Stem Cells
|
US
|
12/477,726
|
3-Jun-09
|
8,252,586
|
28-Aug-12
|
Issued
|
|
3
|
090/006C
|
Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
|
US
|
12/500,998
|
10-Jul-09
|
8,153,428
|
10-Apr-12
|
Issued
|
|
|
090/007C
|
Neural Cell Populations from Primate Pluripotent Stem Cells
|
US
|
13/561,296
|
30-Jul-12
|
|
|
Pending
|
|
|
091/004
|
cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
|
US
|
09/688,031
|
10-Oct-00
|
6,667,176
|
23-Dec-03
|
Issued
|
|
|
091/009C
|
Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
|
US
|
10/039,956
|
23-Oct-01
|
7,041,438
|
9-May-06
|
Issued
|
|
|
091/011P
|
Embryonic Stem Cells Having Genetic Modifications
|
US
|
10/948,956
|
24-Sep-04
|
7,413,904
|
19-Aug-08
|
Issued
|
|
|
091/030P
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
US
|
10/235,094
|
4-Sep-02
|
7,410,798
|
12-Aug-08
|
Issued
|
|
|
091/031D
|
Medium for Growing Human Embryonic Stem Cells
|
US
|
10/873,922
|
21-Jun-04
|
7,297,539
|
20-Nov-07
|
Issued
|
|
|
091/033P
|
Medium for Growing Human Embryonic Stem Cells
|
US
|
10/949,181
|
24-Sep-04
|
7,455,983
|
25-Nov-08
|
Issued
|
|
|
091/037C
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
US
|
12/170,219
|
9-Jul-08
|
|
|
Pending
|
|
4
|
091/038C
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
US
|
12/710,078
|
22-Feb-10
|
|
|
Pending
|
|
|
091/039C
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
US
|
12/763,884
|
20-Apr-10
|
8,097,458
|
17-Jan-12
|
Issued
|
|
|
091/040C
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
US
|
13/323,567
|
12-Dec-11
|
|
|
Pending
|
|
|
091/051
|
Suspension Culture of Human Embryonic Stem Cells
|
US
|
11/917,993
|
18-Dec-07
|
|
|
Pending
|
|
|
091/201AU
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
AU
|
11128/01
|
10-Jan-01
|
751321
|
5-Dec-02
|
Issued
|
|
|
091/202IL
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Xxxxx
|
XX
|
000000
|
10-Jan-01
|
141742
|
10-Dec-06
|
Issued
|
|
|
091/204JP D
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
JP
|
2001-138021
|
10-Jan-01
|
4919445
|
10-Feb-12
|
Issued
|
|
|
091/205SG
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
SG
|
200101413-3
|
10-Jan-01
|
79595
|
31-Dec-08
|
Issued
|
|
|
091/206IN
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
IN
|
00361/CHENP/2001
|
10-Jan-01
|
219103
|
25-Apr-08
|
Issued
|
|
5
|
091/207CA
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Xxxxx
|
XX
|
0000000
|
10-Jan-01
|
2,388,811
|
6-Oct-09
|
Issued
|
|
|
091/209EP
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
EP
|
01900997.6
|
10-Jan-01
|
|
|
Pending
|
|
|
091/211HK
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
HK
|
03107166
|
10-Jan-01
|
|
|
Pending
|
|
|
091/212IL D
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Xxxxx
|
XX
|
000000
|
10-Jan-01
|
177324
|
30-Mar-12
|
Issued
|
|
|
091/217IN D2
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
IN
|
4588/CHENP/2006
|
10-Jan-01
|
238318
|
28-Jan-10
|
Issued
|
|
|
091/218CN D
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
CN
|
200910129670.2
|
10-Jan-01
|
|
|
Pending
|
|
|
091/219EP D
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
EP
|
10175090.9
|
10-Jan-01
|
|
|
Pending
|
|
|
091/220HK
|
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells
|
HK
|
11106881.6
|
10-Jan-01
|
|
|
Pending
|
|
|
091/301AU
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
AU
|
2002323593
|
5-Sep-02
|
2002323593
|
11-Oct-07
|
Issued
|
|
6
|
091/303UK
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
GB
|
0404910.2
|
5-Sep-02
|
2394723
|
20-Jul-05
|
Issued
|
|
|
091/304EP
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
EP
|
02757586.9
|
5-Sep-02
|
|
|
Pending
|
|
|
091/305IL
|
Culture System for Rapid Expansion of Human Embryonic Stem Xxxxx
|
XX
|
000000
|
5-Sep-02
|
160403
|
17-Sep-10
|
Issued
|
|
|
091/306JP
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
JP
|
2003-525623
|
5-Sep-02
|
|
|
Pending
|
|
|
091/307SG
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
SG
|
200400924-7
|
5-Sep-02
|
102946
|
31-May-06
|
Issued
|
|
|
091/314EP D
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
EP
|
10174954.7
|
5-Sep-02
|
|
|
Pending
|
|
|
091/315IL D
|
Culture System for Rapid Expansion of Human Embryonic Stem Xxxxx
|
XX
|
000000
|
5-Sep-02
|
|
|
Pending
|
|
|
091/316JP D
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
JP
|
2009-271501
|
5-Sep-02
|
|
|
Pending
|
|
|
091/317HK
|
Culture System for Rapid Expansion of Human Embryonic Stem Cells
|
HK
|
11106437.5
|
5-Sep-02
|
|
|
Pending
|
|
7
|
091/402EP
|
Medium for Growing Human Embryonic Stem Cells
|
EP
|
05775294.1
|
13-Jul-05
|
|
|
Pending
|
|
|
091/403AU
|
Medium for Growing Human Embryonic Stem Cells
|
AU
|
0000000000
|
13-Jul-05
|
0000000000
|
31-Mar-11
|
Issued
|
|
|
091/404UK
|
Medium for Growing Human Embryonic Stem Cells
|
GB
|
0702793.1
|
13-Jul-05
|
2431165
|
1-Apr-09
|
Issued
|
|
|
091/405IL
|
Medium for Growing Human Embryonic Stem Xxxxx
|
XX
|
000000
|
13-Jul-05
|
180447
|
1-Feb-12
|
Issued
|
|
|
091/406SG
|
Medium for Growing Human Embryonic Stem Cells
|
SG
|
200700160-5
|
13-Jul-05
|
128950
|
30-Jun-09
|
Issued
|
|
|
091/407HK
|
Medium for Growing Human Embryonic Stem Cells
|
HK
|
07110996.6
|
13-Jul-05
|
1103106
|
17-Jul-09
|
Issued
|
|
|
091/408EP D
|
Medium for Growing Human Embryonic Stem Cells
|
EP
|
10180759.2
|
13-Jul-05
|
|
|
Pending
|
|
|
091/501AU
|
Suspension Culture of Human Embryonic Stem Cells
|
AU
|
2006262369
|
20-Jun-06
|
2006262369
|
18-Oct-12
|
Issued
|
|
|
091/502CA
|
Suspension Culture of Human Embryonic Stem Xxxxx
|
XX
|
0000000
|
20-Jun-06
|
|
|
Pending
|
|
|
091/503EP
|
Suspension Culture of Human Embryonic Stem Cells
|
EP
|
06785185.7
|
20-Jun-06
|
|
|
Pending
|
|
|
091/504GB
|
Suspension Culture of Human Embryonic Stem Cells
|
GB
|
0800365.9
|
20-Jun-06
|
2441488
|
29-Sep-10
|
Issued
|
|
8
|
091/505IL
|
Suspension Culture of Human Embryonic Stem Xxxxx
|
XX
|
000000
|
20-Jun-06
|
188264
|
30-Mar-12
|
Issued
|
|
|
091/506IN
|
Suspension Culture of Human Embryonic Stem Cells
|
IN
|
81/CHENP/2008
|
20-Jun-06
|
|
|
Pending
|
|
|
091/507JP
|
Suspension Culture of Human Embryonic Stem Cells
|
JP
|
2008-518312
|
20-Jun-06
|
|
|
Pending
|
|
|
091/508KR
|
Suspension Culture of Human Embryonic Stem Cells
|
KR
|
00-0000-0000000
|
20-Jun-06
|
|
|
Pending
|
|
|
091/509SG
|
Suspension Culture of Human Embryonic Stem Cells
|
SG
|
200718866-7
|
20-Jun-06
|
138384
|
30-Nov-10
|
Issued
|
|
|
091/510CN
|
Suspension Culture of Human Embryonic Stem Cells
|
CN
|
200680027460.7
|
20-Jun-06
|
|
|
Pending
|
|
|
091/511HK
|
Suspension Culture of Human Embryonic Stem Cells
|
HK
|
08102719.8
|
20-Jun-06
|
1122836
|
26-Nov-10
|
Issued
|
|
|
091/512AU D
|
Suspension Culture of Human Embryonic Stem Cells
|
AU
|
2012203350
|
20-Jun-06
|
|
|
Pending
|
|
|
092/002
|
Conditioned Media for Propagating Human Pluripotent Stem Cells
|
US
|
09/900,752
|
6-Jul-01
|
6,642,048
|
4-Nov-03
|
Issued
|
|
|
093/002
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
US
|
09/718,308
|
20-Nov-00
|
6,458,589
|
1-Oct-02
|
Issued
|
|
9
|
093/003D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
US
|
09/872,182
|
31-May-01
|
6,506,574
|
14-Jan-03
|
Issued
|
|
|
093/004P
|
Process for Making Hepatocytes from Pluripotent Stem Cells
|
US
|
10/001,267
|
31-Oct-01
|
7,256,042
|
14-Aug-07
|
Issued
|
|
|
093/005P
|
Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
|
US
|
10/087,142
|
1-Mar-02
|
7,282,366
|
16-Oct-07
|
Issued
|
|
|
093/030P
|
Protocols for Making Hepatocytes from Embryonic Stem Cells
|
US
|
10/810,311
|
26-Mar-04
|
7,473,555
|
6-Jan-09
|
Issued
|
|
|
093/032C
|
Protocols for Making Hepatocytes from Embryonic Stem Cells
|
US
|
12/277,136
|
24-Nov-08
|
|
|
Pending
|
|
|
093/041
|
Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
|
US
|
12/303,104
|
1-Dec-08
|
8,148,151
|
3-Apr-12
|
Issued
|
Univ. Edinburgh
(CONSENT REQUIRED)
|
|
093/201AU
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
AU
|
2001259170
|
26-Apr-01
|
2001259170
|
11-May-06
|
Issued
|
|
|
093/202CA
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Xxxxx
|
XX
|
0000000
|
26-Apr-01
|
2,407,505
|
23-Oct-07
|
Issued
|
|
|
093/204EP
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
EP
|
01932661
|
26-Apr-01
|
|
|
Pending
|
|
|
093/205KR
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
KR
|
2002-7014467
|
26-Apr-01
|
00-0000000
|
13-Jun-07
|
Issued
|
|
10
|
093/206IN
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
IN
|
IN/PCT/2002/01764/CHE
|
26-Apr-01
|
208929
|
16-Aug-07
|
Issued
|
|
|
093/207IL
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Xxxxx
|
XX
|
000000
|
26-Apr-01
|
152481
|
1-Mar-11
|
Issued
|
|
|
093/208JP
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
JP
|
2001-578620
|
26-Apr-01
|
|
|
Pending
|
|
|
093/209SG
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
SG
|
200206520-9
|
26-Apr-01
|
92,561
|
31-Mar-05
|
Issued
|
|
|
093/210GB
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
GB
|
0227573.3
|
26-Apr-01
|
2,380,490
|
29-Dec-04
|
Issued
|
|
|
093/211AU D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
AU
|
2004205306
|
26-Apr-01
|
2004205306
|
14-Apr-05
|
Issued
|
|
|
093/211HK
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
HK
|
03108081
|
26-Apr-01
|
|
|
Pending
|
|
|
093/213CN D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
CN
|
201010528128.7
|
26-Apr-01
|
|
|
Pending
|
|
|
093/214EP D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
EP
|
010175113.9
|
26-Apr-01
|
|
|
Pending
|
|
|
093/215KR D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
KR
|
2007-7003241
|
26-Apr-01
|
00-0000000
|
6-Nov-08
|
Issued
|
|
|
093/216IN D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
IN
|
437/CHENP/2007
|
26-Apr-01
|
238673
|
17-Feb-10
|
Issued
|
|
11
|
093/218JP D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
JP
|
2012-139735
|
26-Apr-01
|
|
|
Pending
|
|
|
093/221AU D
|
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
|
AU
|
2004205307
|
26-Apr-01
|
2004205307
|
7-Apr-05
|
Issued
|
|
|
093/401EP
|
Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
|
EP
|
07795625.8
|
1-Jun-07
|
|
|
Pending
|
Univ. Edinburgh (CONSENT REQUIRED)
|
|
093/402UK
|
Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
|
GB
|
0823060.9
|
1-Jun-07
|
2453074
|
22-Jun-11
|
Issued
|
Univ. Edinburgh (CONSENT REQUIRED)
|
|
094/004D
|
Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
|
US
|
09/872,183
|
31-May-01
|
6,833,269
|
21-Dec-04
|
Issued
|
|
|
094/005C
|
Neural Progenitor Cell Populations
|
US
|
11/281,040
|
16-Nov-05
|
8,148,148
|
3-Apr-12
|
Issued
|
|
|
094/006C
|
Neural Progenitor Cell Populations
|
US
|
12/332,783
|
11-Dec-08
|
8,252,585
|
28-Aug-12
|
Issued
|
|
|
094/007C
|
Neural Progenitor Cell Populations
|
US
|
13/558,078
|
25-Jul-12
|
|
|
Pending
|
|
|
094/011P
|
Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
|
US
|
10/157,288
|
28-May-02
|
7,250,294
|
31-Jul-07
|
Issued
|
|
|
094/013D
|
Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
|
US
|
11/009,504
|
10-Dec-04
|
7,763,463
|
27-Jul-10
|
Issued
|
|
12
|
094/201IN
|
A Medical Composition Comprising Neural Cells
|
IN
|
397/MAS/2001
|
16-May-01
|
231156
|
3-Mar-09
|
Issued
|
|
|
094/202AU
|
Neural Progenitor Cell Populations
|
AU
|
2001263199
|
16-May-01
|
2001263199
|
16-Sep-04
|
Issued
|
|
|
094/203CA
|
Neural Progenitor Cell Populations
|
CA
|
2409698
|
16-May-01
|
2,409,698
|
26-Oct-10
|
Issued
|
|
|
094/204CN
|
Neural Progenitor Cell Populations
|
CN
|
01809662.X
|
16-May-01
|
100580079
|
13-Jan-10
|
Issued
|
|
|
094/205EP
|
Neural Progenitor Cell Populations
|
EP
|
01937463.6
|
16-May-01
|
|
|
Pending
|
|
|
094/206IL
|
Neural Progenitor Cell Populations
|
IL
|
152741
|
16-May-01
|
152741
|
1-May-11
|
Issued
|
|
|
094/207JP
|
Neural Progenitor Cell Populations
|
JP
|
2001-585312
|
16-May-01
|
|
|
Pending
|
|
|
094/208KR
|
Neural Progenitor Cell Populations
|
KR
|
2002-7015192
|
16-May-01
|
903755
|
12-Jun-09
|
Issued
|
|
|
094/209SG
|
Neural Progenitor Cell Populations
|
SG
|
200206677-7
|
16-May-01
|
92,904
|
30-Dec-04
|
Issued
|
|
|
094/210GB
|
Neural Progenitor Cell Populations
|
GB
|
0229369.4
|
16-May-01
|
2,379,447
|
29-Dec-04
|
Issued
|
|
|
094/211HK
|
Neural Progenitor Cell Populations
|
HK
|
03108154.2
|
16-May-01
|
1055765
|
30-Sep-10
|
Issued
|
|
|
094/212JP D
|
Neural Progenitor Cell Populations
|
JP
|
2012-260896
|
16-May-01
|
|
|
Pending
|
|
|
094/221AU D
|
Neural Progenitor Cell Populations
|
AU
|
0000000000
|
16-May-01
|
0000000000
|
16-Aug-07
|
Issued
|
|
|
094/301AU
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
AU
|
2002322270
|
20-Jun-02
|
2002322270
|
1-Oct-09
|
Issued
|
|
13
|
094/303CN
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
CN
|
02815144.5
|
20-Jun-02
|
100384986
|
30-Apr-08
|
Issued
|
|
|
094/304EP
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
EP
|
02756248.7
|
20-Jun-02
|
|
|
Pending
|
|
|
094/305GB
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
GB
|
0400167.3
|
20-Jun-02
|
2,393,733
|
14-Sep-05
|
Issued
|
|
|
094/306IN
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
IN
|
2018/CHENP/2003
|
20-Jun-02
|
224902
|
24-Oct-08
|
Issued
|
|
|
094/307IL
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
IL
|
159324
|
20-Jun-02
|
159324
|
31-Jul-12
|
Issued
|
|
|
094/308JP
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
JP
|
2003-507255
|
20-Jun-02
|
4526265
|
11-Jun-10
|
Issued
|
|
|
094/309KR
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
KR
|
2003-7016718
|
20-Jun-02
|
|
|
Pending
|
|
14
|
094/310SG
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
SG
|
200307601-5
|
20-Jun-02
|
101,708
|
30-Dec-05
|
Issued
|
|
|
094/311HK
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
HK
|
05107808.2
|
20-Jun-02
|
1075673
|
6-Feb-09
|
Issued
|
|
|
094/312CN D
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
CN
|
200610101371.4
|
20-Jun-02
|
101029302
|
30-Mar-11
|
Issued
|
|
|
094/316IN D
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
IN
|
5529/CHENP/2007
|
20-Jun-02
|
247544
|
18-Apr-11
|
Issued
|
|
|
094/318JP D
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
JP
|
2010-009966
|
20-Jun-02
|
|
10-Dec-12
|
Issued
|
|
|
094/319JP D2
|
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Xxxxxxxxx'x Disease
|
JP
|
2012-246396
|
20-Jun-02
|
|
|
Pending
|
|
15
|
096/003
|
Differentiated Cells Suitable For Human Therapy
|
US
|
09/783,203
|
13-Feb-01
|
6,576,464
|
10-Jun-03
|
Issued
|
|
|
096/004
|
Selective Antibody Targeting of Undifferentiated Stem Cells
|
US
|
09/995,419
|
26-Nov-01
|
6,921,665
|
26-Jul-05
|
Issued
|
Univ. Edinburgh (CONSENT REQUIRED)
|
|
096/007C
|
Differentiated Cells Suitable For Human Therapy
|
US
|
11/359,341
|
21-Feb-06
|
|
|
Pending
|
|
|
096/201AU
|
Differentiated Stem Cells Suitable for Human Therapy
|
AU
|
2002237681
|
26-Nov-01
|
2002237681
|
22-Mar-07
|
Issued
|
|
|
096/202CA
|
Differentiated Stem Cells Suitable for Human Therapy
|
CA
|
2434760
|
26-Nov-01
|
|
|
Pending
|
|
|
096/204EP
|
Differentiated Stem Cells Suitable for Human Therapy
|
EP
|
01986488.3
|
26-Nov-01
|
|
|
Pending
|
|
|
096/205GB
|
Differentiated Stem Cells Suitable for Human Therapy
|
GB
|
0313389.9
|
26-Nov-01
|
2,386,120
|
9-Mar-05
|
Issued
|
|
|
096/207IL
|
Differentiated Cells Suitable for Human Therapy
|
IL
|
155695
|
26-Nov-01
|
155695
|
1-Feb-08
|
Issued
|
|
|
096/208IN
|
Differentiated Stem Cells Suitable for Human Therapy
|
IN
|
00782/CHENP/2003
|
26-Nov-01
|
229151
|
13-Feb-09
|
Issued
|
|
|
096/211SG
|
Differentiated Stem Cells Suitable for Human Therapy
|
SG
|
200302425-4
|
26-Nov-01
|
96,763
|
31-Jul-06
|
Issued
|
|
|
096/213CN D
|
Differentiated Stem Cells Suitable for Human Therapy
|
CN
|
200910224980.2
|
26-Nov-01
|
|
|
Pending
|
|
|
096/218IN D
|
A Modified Population of Cells Differentiated from Primate Pluripotent Stem (pPS) Cells
|
IN
|
1873/CHENP/2003
|
26-Nov-01
|
|
|
Pending
|
|
16
|
096/300GB
|
Selective Antibody Targeting of Undifferentiated Stem Cells
|
GB
|
0128409
|
27-Nov-01
|
2,374,076
|
25-Feb-04
|
Issued
|
Univ. Edinburgh (CONSENT REQUIRED)
|
|
097/201AU
|
Tolerizing Allografts of Pluripotent Stem Cells
|
AU
|
2002239294
|
21-Nov-01
|
2002239294
|
28-Aug-06
|
Issued
|
|
|
097/205GB
|
Tolerizing Allografts of Pluripotent Stem Cells
|
GB
|
0313387.3
|
21-Nov-01
|
2,386,125
|
23-Feb-05
|
Issued
|
|
|
097/211SG
|
Tolerizing Allografts of Pluripotent Stem Cells
|
SG
|
200302419-7
|
21-Nov-01
|
96,450
|
31-Jul-07
|
Issued
|
|
|
098/201AU
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells
|
AU
|
2002322379
|
3-Jul-02
|
2002322379
|
15-Feb-07
|
Issued
|
|
|
098/202CA
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Xxxxx
|
XX
|
0000000
|
3-Jul-02
|
|
|
Pending
|
|
|
098/204EP
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells
|
EP
|
02756367.5
|
3-Jul-02
|
|
|
Pending
|
|
|
098/205GB
|
Osteoblasts Derived from Human Embryonic Stem Cells
|
GB
|
0400481.8
|
3-Jul-02
|
2,392,674
|
10-Aug-05
|
Issued
|
|
|
098/206IL
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Xxxxx
|
XX
|
000000
|
3-Jul-02
|
159578
|
1-Mar-11
|
Issued
|
|
|
098/209SG
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells
|
SG
|
200400102
|
3-Jul-02
|
102,198
|
29-Sep-06
|
Issued
|
|
17
|
098/213CN D
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells
|
CN
|
200910152133.X
|
10-Jul-09
|
|
|
Pending
|
|
|
098/214HK D
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells
|
HK
|
10107815.6
|
3-Jul-02
|
|
|
Pending
|
|
|
098/217IN D
|
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells
|
IN
|
2634/CHENP/2005
|
3-Jul-02
|
236883
|
25-Nov-09
|
Issued
|
|
|
099/003
|
Cardiomyocyte Precursors from Human Embryonic Stem Cells
|
US
|
10/193,884
|
12-Jul-02
|
7,425,448
|
16-Sep-08
|
Issued
|
|
|
099/004P
|
Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
|
US
|
10/805,099
|
19-Mar-04
|
7,732,199
|
8-Jun-10
|
Issued
|
|
|
099/006D
|
Differentiation Protocol for Making Human Cardiomyocytes
|
US
|
11/040,691
|
21-Jan-05
|
7,763,464
|
27-Jul-10
|
Issued
|
|
|
099/031
|
Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
|
US
|
11/086,709
|
21-Mar-05
|
7,452,718
|
18-Nov-08
|
Issued
|
|
|
099/032C
|
Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
|
US
|
12/210,779
|
15-Sep-08
|
7,897,389
|
1-Mar-11
|
Issued
|
|
|
099/033C
|
Differentiation Protocol for Making Human Cardiomyocytes
|
US
|
12/234,916
|
22-Sep-08
|
7,851,167
|
14-Dec-10
|
Issued
|
|
18
|
099/041
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
US
|
11/471,916
|
20-Jun-06
|
|
|
Pending
|
|
|
099/201AU
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
AU
|
2002313670
|
12-Jul-02
|
2002313670
|
30-Jul-09
|
Issued
|
|
|
099/202CA
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Xxxxx
|
XX
|
0000000
|
12-Jul-02
|
|
|
Pending
|
|
|
099/203CN
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
CN
|
02813927.5
|
12-Jul-02
|
|
|
Pending
|
|
|
099/204EP
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
EP
|
02753376.9
|
12-Jul-02
|
|
|
Pending
|
|
|
099/205GB
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
GB
|
0400570.8
|
12-Jul-02
|
2,393,734
|
27-Jul-05
|
Issued
|
|
|
099/206IL
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Xxxxx
|
XX
|
000000
|
12-Jul-02
|
159,580
|
8-Nov-08
|
Issued
|
|
19
|
099/207IN
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
IN
|
00033/CHENP/2004
|
12-Jul-02
|
250850
|
1-Feb-12
|
Issued
|
|
|
099/208JP
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
JP
|
2003-512669
|
12-Jul-02
|
|
|
Pending
|
|
|
099/209SG
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
SG
|
200400096-4
|
12-Jul-02
|
101,797
|
27-Jan-06
|
Issued
|
|
|
099/211HK
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
HK
|
05100018.3
|
12-Jul-02
|
|
|
Pending
|
|
|
099/212KR D
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
KR
|
2010-7000243
|
12-Jul-02
|
00-0000000
|
7-Oct-11
|
Issued
|
|
|
099/214JP D
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
JP
|
2010-219095
|
12-Jul-02
|
|
|
Pending
|
|
|
099/215IN D
|
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells
|
IN
|
7542/CHENP/2011
|
12-Jul-02
|
|
|
Pending
|
|
|
099/301AU
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine
|
AU
|
2005224670
|
18-Mar-05
|
2005224670
|
00-Xxx-00
|
Xxxxxx
|
|
00
|
000/000XX
|
Xxxxxx for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Xxxxxxxx
|
XX
|
0000000
|
18-Mar-05
|
|
|
Pending
|
|
|
099/303CN
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine
|
CN
|
200580008779
|
18-Mar-05
|
|
|
Pending
|
|
|
099/304EP
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine
|
EP
|
05732662.1
|
18-Mar-05
|
|
|
Pending
|
|
|
099/305GB
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine
|
GB
|
0619719.8
|
18-Mar-05
|
2,427,873
|
10-Sep-08
|
Issued
|
|
|
099/306IL
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Xxxxxxxx
|
XX
|
000000
|
18-Mar-05
|
178006
|
1-Dec-11
|
Issued
|
|
|
099/307IN
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine
|
IN
|
5842/DELNP/2006
|
18-Mar-05
|
|
|
Pending
|
|
21
|
099/308JP
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine
|
JP
|
2007-504142
|
18-Mar-05
|
4971131
|
13-Apr-12
|
Issued
|
|
|
099/309SG
|
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine
|
SG
|
200606477-8
|
18-Mar-05
|
125692
|
31-Mar-09
|
Issued
|
|
|
099/401AU
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
AU
|
2006262329
|
20-Jun-06
|
2006262329
|
7-Apr-11
|
Issued
|
|
|
099/402CA
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Xxxxx
|
XX
|
0000000
|
20-Jun-06
|
|
|
Pending
|
|
|
099/403CN
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
CN
|
200680022866.6
|
20-Jun-06
|
|
|
Pending
|
|
|
099/404EP
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
EP
|
06785229.3
|
20-Jun-06
|
|
|
Pending
|
|
|
099/405GB
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
GB
|
0800264.4
|
20-Jun-06
|
2441718
|
6-Oct-10
|
Issued
|
|
|
099/406IL
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Xxxxx
|
XX
|
000000
|
20-Jun-06
|
|
|
Allowed
|
|
22
|
099/407IN
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
IN
|
9175/DELNP/2007
|
20-Jun-06
|
|
|
Pending
|
|
|
099/408JP
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
JP
|
2008-518339
|
20-Jun-06
|
|
|
Pending
|
|
|
099/409KR
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
KR
|
00-0000-0000000
|
20-Jun-06
|
|
|
Pending
|
|
|
099/410SG
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
SG
|
200718867-5
|
20-Jun-06
|
138693
|
30-Nov-10
|
Issued
|
|
|
099/411HK
|
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
|
HK
|
08103905
|
20-Jun-06
|
1109913
|
3-Dec-10
|
Issued
|
|
|
131/011P
|
Using Undifferentiated Embryonic Stem Cells to Control the Immune System
|
US
|
10/949,702
|
24-Sep-04
|
7,799,324
|
00-Xxx-00
|
Xxxxxx
|
Xxxx. Xxxxxxx Xxxxxxx
|
|
131/201AU
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
AU
|
2002366603
|
6-Dec-02
|
2002366603
|
15-Jan-09
|
Issued
|
Univ. Western Ontario
|
|
131/204EP
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
EP
|
02804740.5
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
131/205GB
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
GB
|
0414957.1
|
6-Dec-02
|
2399572
|
7-Jun-06
|
Issued
|
Univ. Western Ontario
|
23
|
131/206IL
|
Hematopoietic Cells from Human Embryonic Stem Xxxxx
|
XX
|
000000
|
6-Dec-02
|
162130
|
1-Sep-10
|
Issued
|
Univ. Western Ontario
|
|
131/208JP
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
JP
|
2003-551273
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
131/210SG
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
SG
|
200403341-1
|
6-Dec-02
|
104768
|
31-Jul-06
|
Issued
|
Univ. Western Ontario
|
|
131/212AU D
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
AU
|
0000000000
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
131/213CN D
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
CN
|
200910174800.4
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
131/214EP D
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
EP
|
10175120.4
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
131/215GB D
|
Use of Undifferentiated Embryonic Stem Cells To Induce Immune Tolerance and Improve Allograft Acceptance
|
GB
|
0503865.8
|
6-Dec-02
|
2412379
|
00-Xxx-00
|
Xxxxxx
|
Xxxx. Xxxxxxx Xxxxxxx
|
|
131/216IL D
|
Hematopoietic Cells from Human Embryonic Stem Xxxxx
|
XX
|
000000
|
6-Dec-02
|
200768
|
0-Xxx-00
|
Xxxxxx
|
Xxxx. Xxxxxxx Xxxxxxx
|
|
131/217KR D
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
KR
|
2010-7024253
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
131/218JP D
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
JP
|
2009-265829
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
24
|
131/219HK
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
HK
|
11109490.3
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
131/220AU D2
|
Hematopoietic Cells from Human Embryonic Stem Cells
|
AU
|
|
6-Dec-02
|
|
|
Pending
|
Univ. Western Ontario
|
|
132/002
|
Islet Cells from Human Embryonic Stem Cells
|
US
|
10/313,739
|
6-Dec-02
|
7,033,831
|
25-Apr-06
|
Issued
|
|
|
132/003D
|
Endoderm Cells from Human Embryonic Stem Cells
|
US
|
11/262,633
|
31-Oct-05
|
7,326,572
|
5-Feb-08
|
Issued
|
|
|
132/004C
|
Islet Cells from Human Embryonic Stem Cells
|
US
|
11/960,477
|
19-Dec-07
|
|
|
Pending
|
|
|
132/005C
|
Islet Cells from Human Embryonic Stem Cells
|
US
|
12/262,536
|
31-Oct-08
|
|
|
Pending
|
|
|
132/006C
|
Islet Cells from Human Embryonic Stem Cells
|
US
|
12/543,875
|
19-Aug-09
|
|
|
Pending
|
|
|
132/007C
|
Drug Screening Using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells
|
US
|
12/762,676
|
19-Apr-10
|
|
|
Pending
|
|
|
132/008C
|
Drug Screening Using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells
|
US
|
12/947,605
|
16-Nov-10
|
|
|
Pending
|
|
|
132/031
|
Differentiation and Enrichment of Islet-Like Cells from Human Pluripotent Stem Cells
|
US
|
12/303,895
|
8-Dec-08
|
|
|
Allowed
|
|
25
|
132/201AU
|
Islet Cells from Human Embryonic Stem Cells
|
AU
|
2002364143
|
6-Dec-02
|
2002364143
|
5-Jun-08
|
Issued
|
|
|
132/202CA
|
Islet Cells from Human Embryonic Stem Xxxxx
|
XX
|
0000000
|
6-Dec-02
|
2,470,539
|
4-Oct-11
|
Issued
|
|
|
132/203CN
|
Islet Cells from Human Embryonic Stem Cells
|
CN
|
02824367.6
|
6-Dec-02
|
1602351
|
30-Mar-11
|
Issued
|
|
|
132/204EP
|
Islet Cells from Human Embryonic Stem Cells
|
EP
|
02799217.1
|
6-Dec-02
|
|
|
Pending
|
|
|
132/205GB
|
Islet Cells from Human Embryonic Stem Cells
|
GB
|
0414958.9
|
6-Dec-02
|
2,399,823
|
15-Feb-06
|
Issued
|
|
|
132/206IL
|
Islet Cells from Human Embryonic Stem Xxxxx
|
XX
|
000000
|
6-Dec-02
|
162131
|
31-Mar-11
|
Issued
|
|
|
132/207IN
|
Islet Cells from Human Embryonic Stem Cells
|
IN
|
1795/DELNP/2004
|
6-Dec-02
|
|
|
Pending
|
|
|
132/208JP
|
Islet Cells from Human Embryonic Stem Cells
|
JP
|
2003-551271
|
6-Dec-02
|
4666567
|
21-Jan-11
|
Issued
|
|
|
132/209KR
|
Islet Cells from Human Embryonic Stem Cells
|
KR
|
2004-7008713
|
6-Dec-02
|
1089591
|
29-Nov-11
|
Issued
|
|
|
132/210SG
|
Islet Cells from Human Embryonic Stem Cells
|
SG
|
200403559-8
|
6-Dec-02
|
104,854
|
31-Aug-06
|
Issued
|
|
|
132/211GB D
|
Islet Cells from Human Embryonic Stem Cells
|
GB
|
0517624.3
|
6-Dec-02
|
2415432
|
6-Sep-06
|
Issued
|
|
|
132/212HK
|
Islet Cells from Human Embryonic Stem Cells
|
HK
|
05106662.9
|
6-Dec-02
|
1074218
|
2-Dec-11
|
Issued
|
|
|
132/213CN D
|
Islet Cells from Human Embryonic Stem Cells
|
CN
|
200710307353.6
|
6-Dec-02
|
|
|
Pending
|
|
26
|
132/214HK
|
Islet Cells from Human Embryonic Stem Cells
|
HK
|
09100086.6
|
6-Dec-02
|
|
|
Pending
|
|
|
132/215AU D
|
Islet Cells from Human Embryonic Stem Cells
|
AU
|
0000000000
|
6-Dec-02
|
0000000000
|
22-Apr-10
|
Issued
|
|
|
132/216IL D
|
Islet Cells from Human Embryonic Stem Xxxxx
|
XX
|
000000
|
6-Dec-02
|
188472
|
31-Mar-11
|
Issued
|
|
|
132/217IN D
|
Islet Cells from Human Embryonic Stem Cells
|
IN
|
6576/DELNP/2009
|
6-Dec-02
|
|
|
Pending
|
|
|
132/218JP D
|
Islet Cells from Human Embryonic Stem Cells
|
JP
|
2008-040781
|
6-Dec-02
|
4917559
|
3-Feb-12
|
Issued
|
|
|
132/219KR D
|
Islet Cells from Human Embryonic Stem Cells
|
KR
|
2008-7002476
|
6-Dec-02
|
00-0000000
|
11-Jan-11
|
Issued
|
|
|
132/220AU D2
|
Islet Cells from Human Embryonic Stem Cells
|
AU
|
2010200610
|
6-Dec-02
|
|
|
Pending
|
|
|
132/221CA D
|
Islet Cells from Human Embryonic Stem Xxxxx
|
XX
|
0000000
|
6-Dec-02
|
|
|
Pending
|
|
|
132/222EP D
|
Islet Cells from Human Embryonic Stem Cells
|
EP
|
10174969.5
|
6-Dec-02
|
|
|
Pending
|
|
|
132/223HK
|
Islet Cells from Human Embryonic Stem Cells
|
HK
|
11106412.4
|
6-Dec-02
|
|
|
Pending
|
|
|
132/224JP D2
|
Islet Cells from Human Embryonic Stem Cells
|
JP
|
2011-258931
|
6-Dec-02
|
|
|
Pending
|
|
|
132/225KR D2
|
Islet Cells from Human Embryonic Stem Cells
|
KR
|
|
|
|
|
Unfiled
|
|
|
133/003C
|
Chondrocyte Precursors Derived from Human Embryonic Stem Cells
|
US
|
11/345,878
|
1-Feb-06
|
7,906,330
|
15-Mar-11
|
Issued
|
|
27
|
133/004C
|
Chondrocyte Precursors Derived from Human Embryonic Stem Cells
|
US
|
13/021,497
|
4-Feb-11
|
|
|
Pending
|
|
|
133/201AU
|
Chondrocyte Precursors Derived from Human Embryonic Stem Cells
|
AU
|
2002366602
|
6-Dec-02
|
2002366602
|
16-Oct-08
|
Issued
|
|
|
133/204EP
|
Chondrocyte Precursors Derived from Human Embryonic Stem Cells
|
EP
|
02804739.7
|
6-Dec-02
|
|
|
Pending
|
|
|
133/206IL
|
Chondrocyte Precursors Derived from Human Embryonic Stem Xxxxx
|
XX
|
000000
|
6-Dec-02
|
162132
|
29-Jun-10
|
Issued
|
|
|
133/207IN
|
Chondrocyte Precursors Derived from Human Embryonic Stem Cells
|
IN
|
1794/DELNP/2004
|
6-Dec-02
|
|
|
Pending
|
|
|
133/209KR
|
Chondrocyte Precursors Derived from Human Embryonic Stem Cells
|
KR
|
2004-7008714
|
6-Dec-02
|
00-0000000
|
27-Jul-10
|
Issued
|
|
|
133/210SG
|
Chondrocyte Precursors Derived from Human Embryonic Stem Cells
|
SG
|
200403261-1
|
6-Dec-02
|
105,123
|
31-Aug-06
|
Issued
|
|
|
135/002
|
A Marker System for Preparing and Characterizing High-Quality Human Embryonic Stem Cells
|
US
|
10/389,431
|
13-Mar-03
|
7,153,650
|
26-Dec-06
|
Issued
|
|
28
|
135/201EP
|
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells
|
EP
|
04757690.5
|
13-Mar-04
|
|
|
Pending
|
|
|
135/202SG
|
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells
|
SG
|
200505876-3
|
13-Mar-04
|
115,079
|
31-Oct-07
|
Issued
|
|
|
135/203GB
|
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells
|
GB
|
0520847.5
|
13-Mar-04
|
2415781
|
18-Jul-07
|
Issued
|
|
|
135/212SG D
|
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells
|
SG
|
200708419-7
|
13-Mar-04
|
151119
|
29-May-09
|
Issued
|
|
|
135/213GB D
|
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells
|
GB
|
0708707.5
|
13-Mar-04
|
2434867
|
7-Nov-07
|
Issued
|
|
|
138/202GB
|
Dendritic Cell Vaccines Made from Embryonic Stem Cells for Treating Cancer
|
GB
|
0703122.2
|
10-Aug-05
|
2431582
|
23-Dec-09
|
Issued
|
|
|
138/204HK
|
Dendritic Cell Vaccines for Treating Cancer Made from Embryonic Stem Cells
|
HK
|
07110697.8
|
10-Aug-05
|
1105429
|
23-Apr-10
|
Issued
|
|
|
151/003
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
US
|
12/412,183
|
26-Mar-09
|
8,093,049
|
10-Jan-12
|
Issued
|
|
29
|
151/004C
|
Systems for Differentiating Pluripotent Stem Cells into Hematopoietic Lineage Cells
|
US
|
13/312,349
|
6-Dec-11
|
|
|
Pending
|
|
|
151/201AU
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
AU
|
2009228215
|
26-Mar-09
|
|
|
Pending
|
|
|
151/202CA
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Xxxxx
|
XX
|
0000000
|
26-Mar-09
|
|
|
Pending
|
|
|
151/203CN
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
CN
|
200980116566.8
|
26-Mar-09
|
|
|
Pending
|
|
|
151/204EP
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
EP
|
09724052.7
|
26-Mar-09
|
|
|
Pending
|
|
|
151/206IL
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Xxxxx
|
XX
|
000000
|
26-Mar-09
|
|
|
Pending
|
|
|
151/207IN
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
IN
|
6087/CHENP/2010
|
26-Mar-09
|
|
|
Pending
|
|
|
151/208JP
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
JP
|
2011-502069
|
26-Mar-09
|
|
|
Pending
|
|
30
|
151/209KR
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
KR
|
2010-7021271
|
26-Mar-09
|
|
|
Pending
|
|
|
151/210SG
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
SG
|
201006607-4
|
26-Mar-09
|
|
|
Pending
|
|
|
151/211HK
|
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
|
HK
|
11105528.7
|
26-Mar-09
|
|
|
Pending
|
|
|
161/002
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
US
|
12/362,190
|
29-Jan-09
|
8,241,907
|
14-Aug-12
|
Issued
|
|
|
161/003C
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
US
|
13/546,381
|
11-Jul-12
|
|
|
Pending
|
|
|
161/201AU
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
AU
|
2009209157
|
29-Jan-09
|
|
|
Pending
|
|
|
161/202CA
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
CA
|
2712891
|
29-Jan-09
|
|
|
Pending
|
|
|
161/203CN
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
CN
|
200980103922.2
|
29-Jan-09
|
|
|
Pending
|
|
|
161/204EP
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
EP
|
09705923.2
|
29-Jan-09
|
|
|
Pending
|
|
|
161/205IL
|
Synthetic Surfaces for Culturing Stem Cell Derived Xxxxxxxxxxxxxx
|
XX
|
000000
|
29-Jan-09
|
|
|
Pending
|
|
31
|
161/206IN
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
IN
|
5135/CHENP/2010
|
29-Jan-09
|
|
|
Pending
|
|
|
161/207JP
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
JP
|
2010-545155
|
29-Jan-09
|
|
|
Pending
|
|
|
161/208KR
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
KR
|
2010-7019066
|
29-Jan-09
|
|
|
Pending
|
|
|
161/209SG
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
SG
|
201005466-6
|
29-Jan-09
|
|
|
Pending
|
|
|
161/210HK
|
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
|
HK
|
11106743.4
|
29-Jan-09
|
|
|
Pending
|
|
|
162/002
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
US
|
12/362,250
|
29-Jan-09
|
|
|
Pending
|
|
|
162/201AU
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
AU
|
2009209167
|
29-Jan-09
|
|
|
Pending
|
|
|
162/202CA
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Xxxxx
|
XX
|
0000000
|
29-Jan-09
|
|
|
Pending
|
|
|
162/203CN
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
CN
|
200980103921.8
|
29-Jan-09
|
|
|
Pending
|
|
|
162/204EP
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
EP
|
09705909.1
|
29-Jan-09
|
|
|
Pending
|
|
32
|
162/205IL
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Xxxxx
|
XX
|
000000
|
29-Jan-09
|
|
|
Pending
|
|
|
162/206IN
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
IN
|
5136/CHENP/2010
|
29-Jan-09
|
|
|
Pending
|
|
|
162/207JP
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
JP
|
2010-545160
|
29-Jan-09
|
|
|
Pending
|
|
|
162/208KR
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
KR
|
2010-7019153
|
29-Jan-09
|
|
|
Pending
|
|
|
162/209SG
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
SG
|
201005462-5
|
29-Jan-09
|
|
|
Pending
|
|
|
162/210HK
|
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
|
HK
|
11102599.8
|
29-Jan-09
|
|
|
Pending
|
|
|
164/003C
|
Synthetic Surfaces for Differentiating Stem Cells into Cardiomyocytes (amended)
|
US
|
12/701,731
|
8-Feb-10
|
|
|
Pending
|
|
|
165/002
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
US
|
12/823,739
|
25-Jun-10
|
8,323,966
|
4-Dec-12
|
Issued
|
|
33
|
165/003C
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
US
|
13/679,663
|
16-Nov-12
|
|
|
Pending
|
|
|
165/201AU
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
AU
|
2010266016
|
25-Jun-10
|
|
|
Pending
|
|
|
165/202CA
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Xxxxxxxxxx
|
XX
|
0000000
|
25-Jun-10
|
|
|
Pending
|
|
|
165/203CN
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
CN
|
201080032011.8
|
25-Jun-10
|
|
|
Pending
|
|
|
165/204IL
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Xxxxxxxxxx
|
XX
|
000000
|
25-Jun-10
|
|
|
Pending
|
|
|
165/205IN
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
IN
|
47/CHENP/2012
|
25-Jun-10
|
|
|
Pending
|
|
|
165/206JP
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
JP
|
2012-517776
|
25-Jun-10
|
|
|
Pending
|
|
|
165/207KR
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
KR
|
2012-7001572
|
25-Jun-10
|
|
|
Pending
|
|
34
|
165/208SG
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
SG
|
201109522-1
|
25-Jun-10
|
|
|
Pending
|
|
|
165/209GB
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
GB
|
1201047.6
|
25-Jun-10
|
|
|
Pending
|
|
|
165/210EP
|
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
|
EP
|
10792733.7
|
25-Jun-10
|
|
|
Pending
|
|
|
166/200PCT
|
Enriched Populations of Cardiomyocyte Lineage Cells from Pluripotent Stem Cells
|
WO
|
PCT/US2012/30799
|
28-Mar-12
|
|
|
Pending
|
|
Geron-Licensed Stem Cell Status Report - Active Cases
|
FILE NO.
|
TITLE
|
COUNTRY
|
APPLICATION
NUMBER
|
FILING
DATE
|
PATENT
NUMBER
|
ISSUE
DATE
|
STATUS
|
ASSIGNEE
|
|
131/004C
|
Reconstructing Hematopoietic Cell Function Using Human Embryonic Stem Cells
|
US
|
10/862,625
|
7-Jun-04
|
|
|
Pending
|
Univ. Western Ontario
|
|
134/002
|
Method of Producing Oligodendrocytes from Human Embryonic Stem Cells for Drug Screening or Treatment of Spinal Cord Injury
|
US
|
10/406,817
|
4-Apr-03
|
7,285,415
|
23-Oct-07
|
Issued
|
Regents Univ. California
|
35
|
134/004C
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
US
|
11/637,632
|
11-Dec-06
|
7,579,188
|
25-Aug-09
|
Issued
|
Regents Univ. California
|
|
134/005D
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
US
|
12/357,244
|
21-Jan-09
|
|
|
Pending
|
Regents Univ. California
|
|
134/201AU
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
AU
|
2003250477
|
11-Jul-03
|
2003250477
|
3-Jul-08
|
Issued
|
Regents Univ. California
|
|
134/202CA
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Xxxxxx
|
XX
|
0000000
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
|
134/203CN
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
CN
|
03816184.2
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
|
134/204EP
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
EP
|
03764084.4
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
36
|
134/205GB
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
GB
|
0502774.3
|
11-Jul-03
|
2,407,822
|
00-Xxx-00
|
Xxxxxx
|
Xxxxxxx Xxxx. Xxxxxxxxxx
|
|
134/206IL
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Xxxxxx
|
XX
|
000000
|
11-Jul-03
|
165645
|
1-Mar-11
|
Issued
|
Regents Univ. California
|
|
134/207IN
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
IN
|
4091/DELNP/2004
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
|
134/208JP
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
JP
|
2005-505090
|
11-Jul-03
|
4823689
|
00-Xxx-00
|
Xxxxxx
|
Xxxxxxx Xxxx. Xxxxxxxxxx
|
|
134/209SG
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
SG
|
200407816-8
|
11-Jul-03
|
108,775
|
31-Jan-07
|
Issued
|
Regents Univ. California
|
37
|
134/210HK
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
HK
|
06113936.4
|
19-Dec-06
|
|
|
Pending
|
Regents Univ. California
|
|
134/211EP D
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
EP
|
10175854.8
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
|
134/212JP D
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
JP
|
2011-047716
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
|
134/213IN D
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
IN
|
4057/DELNP/2011
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
|
134/214HK
|
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury
|
HK
|
11105339.6
|
11-Jul-03
|
|
|
Pending
|
Regents Univ. California
|
|
136/002
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
US
|
13/082,727
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
|
136/201AU
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
AU
|
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
38
|
136/202CA
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
CA
|
|
8-Apr-11
|
|
|
Unfiled
|
Univ. Edinburgh
|
|
136/203CN
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
CN
|
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
|
136/204EP
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
EP
|
11718764.1
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
|
136/205IN
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
IN
|
9325/CHENP/2012
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
|
136/206IL
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
IL
|
222292
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
|
136/207JP
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
JP
|
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
|
136/208SG
|
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof
|
SG
|
201207371-4
|
8-Apr-11
|
|
|
Pending
|
Univ. Edinburgh
|
|
150/001C
|
Method for Producing Dendritic Cells
|
US
|
09/849,499
|
4-May-01
|
7,247,480
|
24-Jul-07
|
Issued
|
Isis Innovation, Ltd.
|
|
150/003C
|
Method for Producing Dendritic Cells
|
US
|
11/789,669
|
24-Apr-07
|
7,473,556
|
6-Jan-09
|
Issued
|
Isis Innovation, Ltd.
|
39
|
150/004C
|
Method for Producing Dendritic Cells
|
US
|
12/326,831
|
2-Dec-08
|
7,781,213
|
24-Aug-10
|
Issued
|
Isis Innovation, Ltd.
|
|
150/005C
|
Method for Producing Dendritic Cells
|
US
|
12/841,064
|
21-Jul-10
|
8,232,100
|
31-Jul-12
|
Issued
|
Isis Innovation, Ltd.
|
|
150/006C
|
Method for Producing Dendritic Cells
|
US
|
13/538,995
|
29-Jun-12
|
|
|
Pending
|
Isis Innovation, Ltd.
|
|
150/201AU
|
Method for Producing Dendritic Cells
|
AU
|
200010584
|
5-Nov-99
|
768,267
|
4-Dec-03
|
Issued
|
Isis Innovation, Ltd.
|
|
150/202CA
|
Dendritic Cell Manipulation
|
CA
|
2350210
|
5-Nov-99
|
|
|
Pending
|
Isis Innovation, Ltd.
|
|
150/203EP
|
Method for Producing Dendritic Cells
|
EP
|
99954148.5
|
5-Nov-99
|
|
|
Pending
|
Isis Innovation, Ltd.
|
|
600/001
|
Lysosomal Targeting of Immunogens
|
US
|
08/006,845
|
22-Jan-93
|
5,633,234
|
27-May-97
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
600/201CA
|
Lysosomal Targeting of Xxxxxxxxxx
|
XX
|
0000000
|
21-Jan-94
|
2,154,445
|
26-Jun-07
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
600/203JP
|
Lysosomal Targeting of Immunogens
|
JP
|
19940517149
|
21-Jan-94
|
3581366
|
30-Jul-04
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
600/204AT
|
Lysosomal Targeting of Immunogens
|
AT
|
94910648.8
|
21-Jan-94
|
180835
|
15-Jun-99
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
600/205DE
|
Lysosomal Targeting of Immunogens
|
DE
|
94910648.8
|
21-Jan-94
|
69418856
|
20-Jan-00
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
600/206DK
|
Lysosomal Targeting of Immunogens
|
DK
|
94910648.8
|
21-Jan-94
|
680513
|
27-Dec-99
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
600/207ES
|
Lysosomal Targeting of Immunogens
|
ES
|
94910648.8
|
21-Jan-94
|
2132395
|
16-Aug-99
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
600/208GR
|
Lysosomal Targeting of Immunogens
|
GR
|
94910648.8
|
21-Jan-94
|
3031026
|
31-Dec-99
|
Issued
|
Xxxxx Xxxxxxx Univ.
|
|
601/201EP
|
Chimeric Vaccines
|
EP
|
02763958.2
|
5-Apr-02
|
|
|
Pending
|
Xxxxx Xxxxxxx Univ.
|
|
601/202CA
|
Chimeric Vaccines
|
CA
|
2446462
|
4-May-02
|
|
|
Pending
|
Xxxxx Xxxxxxx Univ.
|
|
800/001
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
US
|
08/640,444
|
30-Apr-96
|
5,853,719
|
29-Dec-98
|
Issued
|
Duke Univ.
|
40
|
800/002C
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
US
|
09/073,819
|
6-May-98
|
6,306,388
|
23-Oct-01
|
Issued
|
Duke Univ.
|
|
800/003C
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
US
|
09/875,264
|
7-Jun-01
|
7,101,705
|
5-Sep-06
|
Issued
|
Duke Univ.
|
|
800/010P
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
US
|
09/171,916
|
16-Feb-99
|
7,105,157
|
12-Sep-06
|
Issued
|
Duke Univ.
|
|
800/011D
|
RNA-loaded Antigen Presenting Cells
|
US
|
09/667,319
|
22-Sep-00
|
6,670,186
|
30-Dec-03
|
Issued
|
Duke Univ.
|
|
800/012C
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
US
|
11/250,546
|
17-Oct-05
|
7,601,343
|
13-Oct-09
|
Issued
|
Duke Univ.
|
|
800/013D
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
US
|
12/585,028
|
1-Sep-09
|
8,263,066
|
11-Sep-12
|
Issued
|
Duke Univ.
|
|
800/014C
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
US
|
13/554,938
|
20-Jul-12
|
|
|
Pending
|
Duke Univ.
|
|
800/020P
|
Method of Identifying Tumor Antigens that Elicit a T-cell Response
|
US
|
09/302,329
|
30-Apr-99
|
6,387,701
|
14-May-02
|
Issued
|
Duke Univ.
|
41
|
800/201AU
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
AU
|
1997/28213
|
30-Apr-97
|
724267
|
11-Jan-01
|
Issued
|
Duke Univ.
|
|
800/202CA
|
Compositions and Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with XXX
|
XX
|
0000000
|
30-Apr-97
|
2,253,632
|
16-Dec-08
|
Issued
|
Duke Univ.
|
|
800/204JP
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
JP
|
539210/97
|
30-Apr-97
|
3836151
|
4-Aug-06
|
Issued
|
Duke Univ.
|
|
800/213EP D
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
EP
|
06015438.2
|
30-Apr-97
|
|
|
Pending
|
Duke Univ.
|
|
800/214JP D
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
JP
|
2006-129005
|
30-Apr-97
|
3955311
|
11-May-07
|
Issued
|
Duke Univ.
|
|
800/216HK
|
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA
|
HK
|
11108880.3
|
30-Apr-97
|
|
|
Pending
|
Duke Univ.
|
|
811/002
|
In Situ Maturation of Dendritic Cells
|
US
|
10/536,211
|
10-Dec-03
|
7,785,583
|
31-Aug-10
|
Issued
|
Duke Univ.
|
|
811/201AU
|
In Situ Maturation of Dendritic Cells
|
AU
|
2003296439
|
10-Dec-03
|
2003296439
|
10-Jul-09
|
Issued
|
Duke Univ.
|
42
|
821/001
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
US
|
10/362,715
|
24-Feb-03
|
|
|
Allowed
|
Xxxxxx Xxxxxxx
|
|
821/002C
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
US
|
13/479,612
|
24-May-12
|
|
|
Pending
|
Xxxxxx Xxxxxxx
|
|
821/206JP
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
JP
|
522234/02
|
24-Aug-01
|
4610847
|
22-Oct-10
|
Issued
|
Xxxxxx Xxxxxxx
|
|
821/215AT
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
AT
|
19607084
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
|
821/216BE
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
BE
|
19607084
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
|
821/217DK
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
DK
|
19607084
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
|
821/218FR
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
FR
|
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
43
|
821/219IT
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
IT
|
19607084
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
|
821/220NL
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
NL
|
19607084
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
|
821/221SE
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
SE
|
19607084
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
|
821/222UK
|
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells
|
GB
|
019607084
|
24-Aug-01
|
1311658
|
15-Oct-08
|
Issued
|
Xxxxxx Xxxxxxx
|
|
822/002C
|
CD4+ CD25+ Regulatory T Cells from Human Blood
|
US
|
13/530,488
|
22-Jun-12
|
|
|
Pending
|
Argos Therapeutics, Inc.
|
|
822/201AU
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
AU
|
2002257648
|
12-Mar-02
|
2,002,257,648
|
17-Jan-08
|
Issued
|
Argos Therapeutics, Inc.
|
|
822/202BR
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
BR
|
0208076.1
|
12-Mar-02
|
|
|
Pending
|
Argos Therapeutics, Inc.
|
|
822/203CA
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
CA
|
2441213
|
12-Mar-02
|
|
|
Pending
|
Argos Therapeutics, Inc.
|
44
|
822/204CN
|
CD4+ CD25+ Regulatory T Cells from Human Blood
|
CN
|
02809777.7
|
12-Mar-02
|
|
|
Pending
|
Argos Therapeutics, Inc.
|
|
822/206JP
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
JP
|
571855/02
|
12-Mar-02
|
|
|
Pending
|
Argos Therapeutics, Inc.
|
|
822/207KR
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
KR
|
2003-7011970
|
12-Mar-02
|
|
|
Pending
|
Argos Therapeutics, Inc.
|
|
822/208DE
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
DE
|
|
12-Mar-02
|
1379625
|
30-Jun-10
|
Issued
|
Argos Therapeutics, Inc.
|
|
822/209FR
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
FR
|
027273978
|
12-Mar-02
|
1379625
|
30-Jun-10
|
Issued
|
Argos Therapeutics, Inc.
|
|
822/210IE
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
IE
|
027273978
|
12-Mar-02
|
1379625
|
30-Jun-10
|
Issued
|
Argos Therapeutics, Inc.
|
|
822/211NL
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
NL
|
027273978
|
12-Mar-02
|
1379625
|
30-Jun-10
|
Issued
|
Argos Therapeutics, Inc.
|
|
822/212SE
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
SE
|
027273978
|
12-Mar-02
|
1379625
|
30-Jun-10
|
Issued
|
Argos Therapeutics, Inc.
|
|
822/213UK
|
CD4+CD25+ Regulatory T Cells from Human Blood
|
GB
|
027273978
|
12-Mar-02
|
1379625
|
30-Jun-10
|
Issued
|
Argos Therapeutics, Inc.
|
|
830/004C
|
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens
|
US
|
08/458,230
|
2-Jun-95
|
5,851,756
|
22-Dec-98
|
Issued
|
Rockefeller Univ. and Argos
|
|
830/005D
|
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens
|
US
|
09/073,596
|
6-May-98
|
|
|
Pending
|
Rockefeller Univ. and Argos
|
45
|
830/010P
|
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens
|
US
|
08/261,537
|
17-Jun-94
|
5,994,126
|
30-Nov-99
|
Issued
|
Rockefeller Univ. and Argos
|
|
830/201AU
|
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens
|
AU
|
40461/93
|
1-Apr-93
|
687733
|
5-Mar-98
|
Issued
|
Rockefeller Univ. and Argos
|
|
830/202CA
|
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Xxxxxxxxxx
|
XX
|
0000000
|
1-Apr-93
|
2,133,409
|
24-May-11
|
Issued
|
Rockefeller Univ. and Argos
|
|
830/204JP
|
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens
|
JP
|
517738/1993
|
1-Apr-93
|
3649335
|
18-May-05
|
Issued
|
Rockefeller Univ. and Argos
|
|
830/312MN
|
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens
|
MN
|
93911581.2
|
1-Apr-93
|
633,929
|
3-Mar-04
|
Issued
|
Rockefeller Univ. and Argos
|
46
